Tirzepatide
Also known as: Tirzepatide (GIP/GLP-1 dual receptor agonist — Mounjaro, Zepbound)
Tirzepatide is a unimolecular dual GIP and GLP-1 receptor agonist with a half-life of approximately 5 days, enabling once-weekly subcutaneous dosing. It is FDA-approved as Mounjaro for type 2 diabetes (2022), Zepbound for chronic weight management in adults with obesity or overweight with a weight-related comorbidity (2023), and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (2024). It carries a BOXED WARNING for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Who's worth your money for Tirzepatide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (96) of 5 scored sellers
$95.00 · 60mg · 99.9% purity
Best value
Lowest $/mg among scored sellers
$10.00 · 20mg · 99.8% purity
Most tested
20 independent COAs on file
$55.00 · 5mg · 99.9% purity
Average price
$4.01/mg
Sellers
46
45-day trend
-6.3%
40 of 46 sellers have a current price· 35 stale hidden
Top Merit pick
🇺🇸 Prime Peptides96✓ verified at source · just now
$1.58/mg -60.5% vs avg$95.00
60mg
- 🇺🇸 Polaris Peptides88
✓ verified at source · just now
$11.00/mg +174.3% vs avg$55.00
5mg
- 🇺🇸 Bulk Peptides50
✓ verified at source · just now
$16.00/mg +299% vs avg$320
20mg
no purity - 🇭🇰 Hkuppeptide48
✓ verified at source · just now
$0.50/mg -87.5% vs avg$10.00
20mg
- 🇭🇰 zztai Peptide Ltd42
✓ verified at source · 2d ago
$4.67/mg +16.4% vs avg$280
60mg
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Tirzepatide
Get one email when the market actually moves — no newsletter, no noise.
About Tirzepatide
CAS
2023788-19-2
Molecular formula
C225H348N48O68
Sequence
YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPSamide
Typical dose range
2.5–15 mg once weekly subcutaneous injection (research studies mirror clinical titration: start 2.5 mg/week, escalate by 2.5 mg every 4 weeks to max 15 mg/week)
Half-life
~5 days (~120 hours)
COAs for Tirzepatide
478 third-party tests across 56 vendors. Each card links to the full report.
For
Tirzeppatide
by Reta One Labs· batch TZ201026
For
Tirzepatide
by NG Peptide· batch TRZ60-05
For
Tirzepatide
by VoriLabs· batch TR60-2608-B
For
Tirzepatide
by VoriLabs· batch TR60-2608-A
For
Tirzepatide
by Sunrise Bioresearch· batch GLP230JUL26-01
For
Tirzepatide
by Novaglo Research· batch 5001072226TZ
For
Tirzepatide
by Novaglo Research· batch 5001572326TZ
For
Tirzepatide
by Novaglo Research· batch 5000572226TZ
For
Tirzepatide
by NovaForge Labs· batch LOT-TR-QSCT1
For
Tirzepatide
by Velora Biolabs· batch VBL-TR10-1
For
Tirzepatide
by Velora Biolabs· batch VBL-TR30-1
For
Tirzepatide
by Velora Biolabs· batch VBL-TR60-1
For
Tirzepatide
by Novaglo Research· batch 5003071726TZ
For
Tirzepatide
by VoriLabs· batch VoriLabs TR60-2607-F
For
Tirzepatide
by VoriLabs· batch VoriLabs TR60-2607-D
For
Tirzepatide
by VoriLabs· batch VoriLabs TR60-2607-C
For
Tirzepatide
by Crush Research· batch CR-2XAG-60-2607-Purple
For
Tirzepatide
by jdbioworks· batch 2026-002
For
Tirzepatide
by Artisan Aminos· batch AA-TRZ220-049
For
Tirzeptide
by Ignite Peptides· batch IP-2607-127
For
Tirzepatide
by Ignite Peptides· batch IP-2607-797
For
Tirzepatide
by Certified Peptides· batch TIR070226
For
Tirzepatide
by VoriLabs· batch TR60-2606-A
For
Tirzepatide
by NG Peptide· batch TRZ40-15
23 citations indexed for Tirzepatide
Study
Baseline monocyte GIP receptor mRNA expression is associated with reductions in body weight and FIB-4 index after switching to tirzepatide in patients with type 2 diabetes
Background Tirzepatide improves body weight and glycemic control in patients with type 2 diabetes, but factors associated with inter-individual differences after switching remain unclear.
cohort · 2026
Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort
While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness.
Study · 2026
PET Imaging of Dual GLP-1R and GIPR Targeting with [18F]AlF-NOTA-Asp2-Tirzepatide
Tirzepatide is a clinical dual GLP-1R and GIPR agonist for type 2 diabetes and obesity, and non-invasive approaches to assess its in vivo biodistribution and systemic toxicity in living animals remain limited.
cohort · 2026
Comparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS
Background Semaglutide and tirzepatide are widely used for type 2 diabetes and obesity, but comparative post-marketing safety data remain limited.
case-report · 2026
Tirzepatide-associated severe euvolemic hyponatremia with syndrome of inappropriate antidiuretic hormone secretion-compatible biochemical features
Abstract Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist that is being increasingly used for the management of type 2 diabetes mellitus and obesity.
Study · 2026
Bariatric Surgery as a Rescue Strategy After Semaglutide or Tirzepatide
Objective To evaluate 2-year weight loss after bariatric surgery among adults with intolerable adverse effects or inadequate weight loss with semaglutide or tirzepatide.